SKU: OPC-CEREBROLYSIN-10ML
Cerebrolysin Solution for Injection contains Cerebroprotein Hydrolysate 215.2mg/ml and is a prescription neurotrophic medicine used under medical supervision for selected neurological conditions.
Cerebrolysin Solution for Injection 10ml contains Cerebroprotein Hydrolysate 215.2mg/ml and is a prescription neurological medicine used under the supervision of a qualified healthcare professional. It is a neurotrophic preparation that is used in selected neurological conditions involving the brain and nervous system.
Cerebrolysin contains low-molecular-weight peptides derived from porcine brain proteins. It is used in clinical settings where support for neuronal function and protection of nerve cells is considered appropriate. Its use, dose and duration depend on the patient's diagnosis and the treatment plan established by the treating physician.
The medicine may be considered in conditions such as stroke, traumatic brain injury and certain forms of dementia. Treatment should be individualized because neurological conditions can vary considerably from one patient to another.
Explore our healthcare product collection for more pharmaceutical and healthcare products.
Cerebrolysin is a neurotrophic medicine containing Cerebroprotein Hydrolysate. It is designed to provide a mixture of biologically active peptides that may support neuronal function and protective mechanisms within the nervous system.
The medicine is administered by injection and should only be given by an appropriately trained healthcare professional. The route and method of administration depend on the prescribed volume and the patient's medical condition.
Cerebrolysin is available in different ampoule strengths and volumes. The 10ml presentation contains 215.2mg/ml of Cerebroprotein Hydrolysate. Official product information describes intravenous and intramuscular administration depending on the volume being administered.
For general medicine information, you can also visit MedlinePlus.
Cerebrolysin is used under medical supervision for selected neurological conditions. The exact indication and treatment protocol should be decided by the treating physician after assessing the patient's symptoms, diagnosis and overall health.
Cerebrolysin may be used as part of treatment protocols for patients with neurological impairment following stroke. It may be considered to support neurological recovery and functional rehabilitation when prescribed by a specialist.
Cerebrolysin may be used in selected cases involving traumatic brain injury. Such treatment is individualized according to the severity of the injury and the patient's neurological status.
Cerebrolysin may be used in selected patients with dementia-related cognitive impairment under specialist supervision. Treatment decisions depend on the type and severity of cognitive impairment and the overall medical condition.
Cerebrolysin contains neuroactive peptides that are intended to support neuronal function and the survival of nerve cells.
The medicine has neuroprotective properties and may support cellular mechanisms involved in protecting neurons from damage.
When prescribed as part of an appropriate treatment plan, Cerebrolysin may be used alongside rehabilitation and other medical measures to support neurological recovery following certain brain conditions.
In selected neurological conditions involving cognitive impairment, Cerebrolysin may be used under specialist supervision as part of a broader treatment approach.
Cerebrolysin is used in clinical practice for selected neurological conditions including stroke, traumatic brain injury and dementia-related disorders. The appropriate use depends on the individual patient's medical assessment.
Cerebrolysin Solution for Injection contains:
The active preparation is derived from porcine brain proteins and consists of low-molecular-weight peptides and amino acids.
Cerebrolysin is classified as a neurotrophic preparation. Its peptide components are intended to support neuronal processes and mechanisms involved in neuronal protection and repair.
The preparation may influence several biological pathways associated with neuronal survival, cellular protection and recovery. These effects are relevant to the medicine's use in selected neurological conditions.
Because the underlying causes and severity of neurological disorders differ, Cerebrolysin should be used only when specifically recommended by a qualified healthcare professional.
Cerebrolysin is an injectable medicine and should be administered by a qualified healthcare professional. The exact route and administration method depend on the prescribed dose and volume.
Official product guidance states that volumes up to 10ml may be administered by slow intravenous injection, while volumes up to 5ml may be administered intramuscularly. Larger intravenous volumes are diluted and administered as an infusion according to the prescribing instructions.
The solution should be administered promptly after opening the ampoule, and appropriate sterile technique must be maintained during preparation and administration.
For the official administration information, visit Cerebrolysin's official administration guide.
The dosage of Cerebrolysin depends on the neurological condition being treated, its severity and the individual patient's treatment plan. The prescribing doctor determines the appropriate dose and treatment duration.
Official Cerebrolysin guidance lists different daily dosage ranges for conditions including stroke, traumatic brain injury and cognitive disorders. Therefore, patients should not attempt to select a dose or treatment course on their own.
For stroke and traumatic brain injury, official guidance describes daily doses that may range from 20ml to 50ml in specific treatment protocols. For cognitive problems and Alzheimer's disease, the listed range is 10ml to 30ml. These are treatment-guideline ranges and not instructions for self-administration.
Like other medicines, Cerebrolysin may cause unwanted effects in some patients. Reported reactions can include dizziness, headache, sweating, nausea and other temporary discomforts.
Some patients may experience agitation, confusion or sleep-related changes. If symptoms are severe, persistent or unusual, inform the treating healthcare professional promptly.
Headache or dizziness may occur in some patients. If these symptoms are significant or persistent, medical advice should be obtained.
Nausea can occur following administration. Tell your healthcare professional if nausea is severe or does not settle.
Some patients may experience restlessness or agitation. Any significant change in behaviour or mental state should be reported to the treating physician.
Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and supplements before receiving Cerebrolysin.
The medicine should not be mixed in the same solution with certain other medicinal products unless compatibility has been specifically established. Official guidance also advises against mixing Cerebrolysin with balanced amino acid solutions, vitamins and some cardiovascular medicines.
Your healthcare professional will determine which medicines can safely be administered alongside Cerebrolysin.
Patients with severe renal impairment should inform their doctor before treatment. The treating healthcare professional will assess whether Cerebrolysin is appropriate based on kidney function and the overall clinical condition.
Patients with epilepsy or a history of seizures should inform their doctor before receiving Cerebrolysin. The treating physician will consider the patient's neurological history when determining whether treatment is suitable.
Cerebrolysin is an injectable prescription medicine, so appropriate administration technique is important. The route, dilution requirements and injection or infusion rate can depend on the amount prescribed.
Professional administration helps ensure appropriate sterile handling and allows the healthcare team to monitor the patient during treatment.
Store Cerebrolysin in a light-protected place at a temperature not exceeding 25°C, unless the product label states otherwise. Keep it out of the reach of children.
After an ampoule is opened, the solution should be used immediately according to the official product instructions. Do not store leftover solution for later use.
Cerebrolysin is a prescription neurotrophic preparation containing Cerebroprotein Hydrolysate 215.2mg/ml. It is used under medical supervision for selected neurological conditions.
It may be used in selected neurological conditions such as stroke, traumatic brain injury and certain dementia-related disorders, depending on the physician's assessment and treatment protocol.
Cerebrolysin contains Cerebroprotein Hydrolysate 215.2mg/ml.
Cerebrolysin is a prescription injectable medicine and should be administered by an appropriately trained healthcare professional according to the prescribed route and method.
Store it in a light-protected place at a temperature not exceeding 25°C and keep it away from children. Opened ampoules should be used immediately.
Possible adverse effects can include headache, dizziness, sweating and nausea. Contact your healthcare professional if you experience severe or persistent symptoms.
Yes. Cerebrolysin is a prescription-only medicine and should be used under medical supervision.
Cerebrolysin should not be mixed with other medicines or solutions unless compatibility has been confirmed by the healthcare professional. Follow the official preparation instructions.
Visit our healthcare product collection to explore additional pharmaceutical and healthcare products.
For general medicine information, visit MedlinePlus.
This information is provided for general educational purposes and does not replace professional medical advice, diagnosis or treatment. Cerebrolysin is a prescription injectable medicine and should be administered only under the supervision of an appropriately qualified healthcare professional.
Dosage, route of administration, treatment duration and suitability vary according to the patient's medical condition. Always follow the prescribing doctor's instructions and check the original product packaging for the latest product information.
| Brand | Cerebrolysin |
| Manufacturer | Mankind Pharma Ltd |
| Composition | Cerebroprotein Hydrolysate 215.2mg/ml |
| Package | 5 injections |
| Ship time | 5-10 Business Days |
Free Shipping
For all oders over $99
Secure Payment
100% secure payment
24/7 Support
Online top support